Sunday 8 November 2026 Export RCUS’s income statement to Excel — free account

Arcus Biosciences, Inc.

RCUS

Arcus Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $247.0 million, down 4.26% from fiscal 2024.

Revenue: −65.4%
EPS: +20.9%
Free cash flow: +9.28%
Total debt: +4.08%

Quarter to September 2026, against a year earlier

18.28 0.59 +3.34%

Follow RCUS

Alert me

Market cap: $2.5B
P/E: n/m
Fwd P/E: n/m
Dividend yield: —
F-score: 0/9
ROIC: 0.00%
Net debt / EBITDA: 2.3×
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Net sold: $9.3M
Trades: 15 sells · 0 buys
Ownership: 25.4%

Capital & Financial Ratios $m

Size

Market Cap 2,510

Revenue ttm 100

Net income ttm (453)

Free cash flow ttm (465)

Net debt Q (528)

Valuation

P/E n/m

Forward P/E n/m

Price / sales 23.3

Forward P/S Powerpack

Price / FCF n/m

Price / book 6.5

Financial health

Current ratio Q 3.3

Debt / equity Q 0.3

Interest coverage Q (43.7)

Growth

Revenue growth Q −65.4%

Operating income growth Q +7.8%

EPS, this year −8.8%

EPS, next year A +7.8%

Revenue, next year A −71.3%

EPS, past 5 yrs —

EPS, next 5 yrs A +2.6%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates; n/m is not meaningful, as a P/E on a loss. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 60.52%

10-year low 10-year high

P/B against its own 10 years 93.35%

10-year low 10-year high

EV/Sales against its own 10 years 70.68%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	759	978	981	630
Receivables	38	20	11	18
Inventory	—	—	—	—
Other	—	—	—	—
	831	1,016	1,007	664

	2023	2024	2025	Q'26
Payables	17	18	42	44
ST’ Debt	—	—	—	—
Other	76	123	154	141
	184	226	231	199

Compound Annual Growth %

	10y	5y	3y
Sales	—	25.93%	30.16%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	4.67%	(1.34%)

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate −0.92 Actual −1.00

−1.17 −1.04 −0.91 −0.79 −0.66

Q4 FY25 Beat +0.22

Q1 FY26 Miss −0.10

Q2 FY26 Beat +0.26

Q3 FY26 Miss −0.08

Q4 FY26 — Feb 24

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q4 FY25	−1.11	−0.89	Beat by 0.22
Q1 FY26	−0.92	−1.02	Miss by 0.10
Q2 FY26	−0.98	−0.72	Beat by 0.26
Q3 FY26	−0.92	−1.00	Miss by 0.08
Q4 FY26	−0.88	—	Reports 24 February 2027

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(1.02)	(0.72)	(1.00)	—	—
’25	(1.14)	0.00	(1.27)	(0.89)	(3.29)
’24	(0.05)	(1.02)	(1.00)	(1.03)	(3.14)
’23	(1.09)	(1.04)	(0.94)	(1.08)	(4.15)
’22	(0.96)	(0.93)	(0.90)	(0.93)	(3.71)
’21	(1.08)	(1.09)	(1.11)	3.71	0.71
’20	(0.63)	(0.93)	0.03	(0.82)	(2.24)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	17	41	9	—	—
’25	28	160	26	33	247
’24	145	39	48	26	258
’23	25	29	32	31	117
’22	18	27	33	34	112
’21	9	9	9	355	383
’20	2	2	65	10	78

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(138)	(119)	(88)	—	—
’25	(132)	(133)	(97)	(120)	(482)
’24	(2)	(94)	26	(100)	(170)
’23	(98)	(57)	(63)	(88)	(306)
’22	654	(65)	(81)	(70)	438
’21	(66)	(74)	(54)	(62)	(256)
’20	(31)	(24)	216	(50)	111

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(138)	(119)	(88)	—	—
’25	(133)	(133)	(97)	(121)	(484)
’24	(6)	(94)	25	(101)	(176)
’23	(101)	(62)	(73)	(94)	(330)
’22	651	(66)	(83)	(70)	432
’21	(70)	(80)	(62)	(70)	(282)
’20	(31)	(24)	215	(52)	108

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Sep ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	—	1	8	15	78	383	112	117	258	247	100		+90.7%	71	64	106	(24.5%)
	Gross margin, %	0.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00		+100.0 pt	Powerpack Arcus Biosciences, Inc.’s next three years, line by line Analysts expect revenue to shrink 24.5% a year to 2028 — slower than the 90.7% of the last 8 years. See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	(18)	(53)	(50)	(85)	(123)	55	(266)	(301)	(282)	(353)	(453)		+39.2%
	EBT margin, %	0.00	(3,756.69)	(593.73)	(564.73)	(157.69)	14.36	(237.50)	(257.26)	(109.30)	(142.91)	(453.00)		(142.9) pt
	Net income	(18)	(53)	(50)	(85)	(123)	53	(267)	(307)	(283)	(353)	(453)		+39.2%
Per share, $
Per share, $	Revenue	0.00	0.77	0.24	0.34	1.42	5.53	1.56	1.58	2.86	2.30	0.78		n/m
	Earnings	(20.80)	(29.04)	(1.43)	(1.93)	(2.24)	0.76	(3.71)	(4.15)	(3.14)	(3.29)	(3.63)		(18.5%)
	Cash flow	(14.98)	(13.71)	(1.24)	(1.68)	2.03	(3.69)	6.08	(4.14)	(1.89)	(4.49)	(3.65)		(12.5%)
	Capex	(4.74)	(3.02)	(0.11)	(0.04)	(0.05)	(0.38)	(0.08)	(0.32)	(0.07)	(0.02)	0.00		(46.0%)
	Free cash flow	(19.73)	(16.72)	(1.35)	(1.72)	1.97	(4.07)	6.00	(4.46)	(1.95)	(4.51)	(3.65)		(15.1%)
	Book value	0.00	84.17	6.79	3.74	9.17	12.15	9.13	6.24	5.38	5.88	2.81		n/m
	Shares, m	1	2	35	44	55	69	72	74	90	107	122		+70.9%
Valuation, ×
Valuation, ×	P/E	—	0.00	0.00	0.00	0.00	58.65	0.00	0.00	0.00	0.00	0.00		6.5
	P/S	—	0.00	44.64	29.51	18.24	7.32	12.99	12.45	5.20	10.36	23.30		15.6
	P/B	—	0.00	1.59	2.70	2.83	3.33	2.21	3.15	2.77	4.06	6.51		2.5
	EV/Sales	—	0.00	13.92	16.96	9.09	6.33	5.02	6.96	1.60	6.79	18.02		7.4
	EV/FCF	—	4.73	(2.49)	(3.37)	6.56	(8.59)	1.30	(2.47)	(2.34)	(3.47)	(3.86)		(1.1)
Cash, $m
Cash, $m	Operating cash flow	(13)	(25)	(43)	(73)	111	(256)	438	(306)	(170)	(482)	(465)		+49.5%
	Capex	(4)	(6)	(4)	(2)	(3)	(26)	(6)	(24)	(6)	(2)	(2)		(7.7%)
	Free cash flow	(17)	(31)	(47)	(75)	108	(282)	432	(330)	(176)	(484)	(465)		+45.0%
Balance, $m
Balance, $m	Working capital	94	164	242	170	614	1,096	874	647	790	776	465		+26.4%
	Net debt	(99)	(176)	(257)	(188)	(714)	(382)	(892)	(759)	(930)	(882)	(528)		+27.5%
	Shareholders’ equity	—	154	235	164	502	842	657	462	485	631	358		+19.3%
Returns, %
Returns, %	ROA	(18.92)	(55.73)	(21.31)	(35.44)	(25.22)	4.48	(18.18)	(25.16)	(25.21)	(30.84)	(50.56)		(11.9) pt
	ROIC	0.00	0.00	0.00	0.00	0.00	7.34	0.00	0.00	0.00	0.00	0.00		0.0 pt
	ROE	39.07	114.99	(61.00)	(42.48)	(36.93)	7.89	(35.62)	(54.87)	(59.77)	(63.26)	(114.11)		(102.3) pt
People
People	Employees	—	—	108	139	236	366	500	577	627	601	—		+27.8%
	Revenue/emp, $m	—	0.00	0.08	0.11	0.33	1.05	0.22	0.20	0.41	0.41	—		n/m

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 6 Nov 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
BEAM Beam Therapeutics Inc.	$2.7B	— (loss-making)	— (loss-making)	−96.83% (below 0%: shrinking)	n/m	−29.45% (below 0%: shrinking)	100.00%	(46,033.22%)	Compare
VCEL Vericel Corporation	$2.7B	82.9×	98.9×	+26.47% (above 0%: growing)	+176.70% (above 0%: growing)	−19.39% (below 0%: shrinking)	73.34%	14.27%	Compare
ZLAB Zai Lab Limited Unsponsored ADR	$2.6B	— (loss-making)	— (loss-making)	−6.79% (below 0%: shrinking)	n/m	−95.46% (below 0%: shrinking)	0.00%	(58.20%)	Compare
XNCR Xencor, Inc.	$2.5B	— (loss-making)	— (loss-making)	+454.88% (above 0%: growing)	n/m	−52.91% (below 0%: shrinking)	100.00%	19.62%	Compare
RCUS Arcus Biosciences, Inc.	$2.5B	— (loss-making)	— (loss-making)	−65.38% (below 0%: shrinking)	n/m	+9.28% (above 0%: growing)	100.00%	(1,455.56%)
MBX MBX Biosciences, Inc.	$2.3B	— (loss-making)	—	—	n/m	−29.67% (below 0%: shrinking)	—	0.00%	Compare
PHVS Pharvaris N.V.	$2.3B	— (loss-making)	—	—	n/m	−17.31% (below 0%: shrinking)	0.00%	0.00%	Compare
NAMS NewAmsterdam Pharma Company N.V.	$2.3B	— (loss-making)	— (loss-making)	+5,406.90% (above 0%: growing)	n/m	−21.76% (below 0%: shrinking)	100.00%	(230.58%)	Compare
PVLA Palvella Therapeutics, Inc.	$2.3B	— (loss-making)	— (loss-making)	−99.09% (below 0%: shrinking)	n/m	−136.38% (below 0%: shrinking)	100.00%	0.00%	Compare
Median of peers	$2.4B	—	—	+9.84%	—	−29.56%	100.00%	0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 21 April 2026

Chief executive’s pay

Year	Total pay	Actually paid	$100 invested
2025	9.66m	17.73m	89.87
2024	7.28m	4.80m	147.43
2023	10.12m	7.48m	194.36
2022	9.05m	(2.07m)	204.75
2021	9.48m	14.58m	400.69

Ownership

Directors and executive officers, together 7.60%

Gilead Sciences, Inc. 25.10%

BlackRock, Inc. 10.20%

Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Arcus Biosciences, Inc. (RCUS) Latest News

4 Nov

Impact 4 · 4:05 PM · Business Wire

Arcus Biosciences Reports Third-Quarter 2026 Financial Results and Provides a Pipeline Update

24 Oct

Impact 3 · 5:13 PM · Simply Wall St.

How Investors May Respond To Arcus Biosciences (RCUS) $250 Million Share Sale

Impact 3 · 3:09 PM · Simply Wall St.

Arcus Biosciences (RCUS) Stock Looks Stretched As Casdatifan Trial Data Impresses

21 Oct

Impact 4 · 4:22 PM · Business Wire

Arcus Biosciences Announces Commencement of Public Offering of Common Stock

Impact 4 · 10:00 AM · Zacks

Can Expanding Ivonescimab Development Unlock SMMT's Growth Potential?

Impact 4 · 5:02 AM · MarketBeat

Arcus Biosciences Sees $5B-$10B RCC Opportunity for Casdatifan at Investor Day

Impact 3 · 10:53 PM · Business Wire

Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock

Impact 3 · 6:32 PM · Investing.com

Arcus Biosciences stock falls on public offering announcement

Impact 3 · 6:32 PM · Investing.com

Arcus Biosciences stock falls on public offering announcement

Impact 3 · 12:30 PM · Business Wire

William Blair Expands Biotech Research as Veteran Analyst Alethia Young Initiates Coverage

20 Oct

Impact 4 · 8:30 AM · Business Wire

Arcus Presents New Data from ARC-20 that Demonstrate the Opportunity for Casdatifan to Become a Foundational Treatment Across All Lines of Therapy in Kidney Cancer

Impact 3 · 9:31 AM · Investing.com

Arcus stock tumbles 6% after unveiling casdatifan trial data

Impact 3 · 9:00 AM · Zacks

Arcus Biosciences, Inc. (RCUS) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

6 Oct

Impact 3 · 6:09 PM · Simply Wall St.

Is Arcus Biosciences (RCUS) Undervalued As New Casdatifan Data Takes Center Stage?

4 Oct

Impact 4 · 9:06 PM · Simply Wall St.

How Investors Are Reacting To Arcus Biosciences (RCUS) Expansive New Casdatifan ARC-20 Kidney Cancer Data

22 Sep

Impact 4 · 8:30 AM

Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy

13 Aug

Impact 4 · 8:03 PM

Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)’s Cancer Drug Partnership Create a New Treatment Standard?

12 Aug

Impact 3 · 9:14 PM · The Motley Fool transcript

Arcus Biosciences (RCUS) Q2 2026 Earnings Call Transcript

10 Aug

Impact 4 · 12:01 PM

Arcus Biosciences' Casdatifan Therapy Could be Launched in 2028, Morgan Stanley Says

8 Aug

Impact 3 · 11:03 PM · MarketBeat transcript

Arcus Biosciences Q2 Earnings Call Highlights

Impact 3 · 1:10 AM

Arcus Biosciences (RCUS) Stock Gets Fair Value Bump After Casdatifan Optimism

6 Aug

Impact 3 · 8:30 AM · Moby

Arcus Biosciences, Inc. Q2 2026 Earnings Call Summary

5 Aug

Impact 3 · 4:05 PM

Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update

23 Jul

Impact 3 · 10:31 AM

SMMT Shares Updated Ivonescimab Survival Data From NSCLC Study

22 Jul

Impact 3 · 4:35 PM

Arcus Biosciences Announces Clinical Supply Agreement with AVEO Oncology to Evaluate Casdatifan in Combination with Tivozanib for Advanced Kidney Cancer Patients

Impact 3 · 4:30 PM

Arcus Biosciences and Summit Therapeutics Enter Into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer

Impact 3 · 4:30 PM

Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer

1 Jul

Impact 4 · 5:35 PM

Bristol-Myers Squibb (BMY) Joins Arcus Biosciences to Test a New Two-Drug Kidney Cancer Combination

Impact 4 · 11:00 AM

New Research Published in Nature Links Clinical Activity with HIF‑2a Biology in Advanced Kidney Cancer Patients Treated with Casdatifan

4 Jun

Impact 4 · 11:53 AM · Zacks

Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study

Arcus Biosciences, Inc.

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Arcus Biosciences, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 21 April 2026

Chief executive’s pay

Ownership

Arcus Biosciences, Inc. (RCUS) Latest News

4 Nov

24 Oct

21 Oct

20 Oct

6 Oct

4 Oct

22 Sep

13 Aug

12 Aug

10 Aug

8 Aug

6 Aug

5 Aug

23 Jul

22 Jul

1 Jul

4 Jun

RCUS metrics, ten years each

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Arcus Biosciences, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 21 April 2026

Chief executive’s pay

Ownership

Arcus Biosciences, Inc. (RCUS) Latest News

4 Nov

24 Oct

21 Oct

20 Oct

6 Oct

4 Oct

22 Sep

13 Aug

12 Aug

10 Aug

8 Aug

6 Aug

5 Aug

23 Jul

22 Jul

1 Jul

4 Jun

RCUS metrics, ten years each

Stockrow Weekly